Skip to main content
Log in

Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans

  • Correspondence
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Faust SN, Levin M, Harrison OB, et al (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345:408–416

    Article  CAS  PubMed  Google Scholar 

  2. Bernard GR, Vincent JL, Laterre PF, et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709

    CAS  PubMed  Google Scholar 

  3. Wcisel G, Joyce D, Gudmundsdottir A, Shasby DM (2002) Human recombinant activated protein C in meningococcal sepsis. Chest 121:292–295

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Esther B. Bachli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bachli, E.B., Vavricka, S.R., Walter, R.B. et al. Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans. Intensive Care Med 29, 337 (2003). https://doi.org/10.1007/s00134-002-1605-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-002-1605-y

Keywords

Navigation